LegislationPeer-reviewed
FDA Moves to Bar Bulk Compounding of GLP-1 Weight-Loss Drugs
A federal proposal would remove semaglutide, tirzepatide, and liraglutide from the list of drugs that outsourcing facilities may compound in bulk, reshaping many med-spa programs.